You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大行評級|中泰國際:上調聯邦制藥評級至“增持” 目標價微升至9.7港元
格隆匯 10-23 10:54
中泰國際發佈研究報吿稱,將聯邦制藥評級由“買入”上調至“增持”,目標價從9.68港元微升至9.7港元;由於預計2023年下半年胰島素與動保業務銷售情況將好於早前預測,將2023-25E收入預測上調2.1%、1.7%、1.9%,股東淨利潤預測上調0.4%、1.2%、0.3%。報吿稱,公司管理層表示首款GLP-1激動劑利拉魯肽已提交上市申請,預計2024年內有望獲批上市。按照目前進度,公司預計長效胰島素德谷胰島素有望於2025年獲批上市。關於近期市場關注的司美格魯肽,公司目前正在進行臨牀試驗,預計糖尿病與體重管理適應症分別有望於2025年及2027年獲批。公司屬於香港上市企業中較早獲批司美格魯肽臨牀試驗的企業之一,由於司美格魯肽在降糖與減重方面效果優異,因此如未來臨牀數據良好,將受資金關注。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account